Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, Inc. Carole has built an integrated development organization that is responsible for advancing therapeutic candidates from IND enabling toxicology through Phase 1 to Phase 3 testing. Under Carole’s leadership, Denali has advanced more than five programs into clinical development since Denali’s founding in 2015 across therapeutic areas including Rare Disease, Parkinson’s disease, Alzheimer’s disease, and ALS.